This article is from page 18 of the 2012-06-19 edition of The Clare People. OCR mistakes are to be expected so download the original SWF or the rendered page 18 JPG
THE fact that the Roche Ireland plant in Clarecastle has an incinerator is being held up as the trump card that can save the company from being closed as part of a global restructuring plan being put in place by the company’s cor porate headquar ters in Basel in Switzerland.
Permission in principal for an incinerator at the Clarecastle operation was granted by Clare County Council in early 1996, but was later the subject of the first ever Envi ronmental Protection Agency Oral Hearing before the Roche was granted a licence for the incineration facility in December of that year.
Sixteen years on and with the incineration facility firmly in place, there are hopes among the staff that this could be “the deciding factor” in persuading the Roche Group to retain its Clarecastle operation.
Despite controversies such as incineration and the odour problem that dogged the Clarecastle area in the early years of the plant, Syntex/ Roche’s reputation as a flagship employer in the county has been cemented over many years.
This was flagged from its earliest days of production in 1977, when it employed 180 people and had a wage bill of £750, 000, while within four years numbers employed at the plant had grown to nearly 300 as the company embarked on a £7. 5m investment.
Thanks to the production of the naproxen drug, Syntex had an initial turnover of £10m, a figure that trebled in the early ’80s as employment soared and an expansion of facilities allowed for a four-cycle seven-day week operation.
In 1994 the Clarecastle company became part of the Pharmaceutical Division of the Roche Group as it acquired the Syntex Cor poration in a $5.3bn worldwide takeover that resulted in it being re-branded as Roche Ireland from 1996.
Employees at the Clarecastle plant come from a wide range of disciplines and include chemists, engineers, manufacturing and laboratory technicians, craft-workers, accountants and IT specialists.
There are four automated manufacturing plants on site with room for further expansion, with the company priding itself of being “a manufacturing centre of excellence for the production of active pharmaceutical ingredients destined for conversion to medicines in dosage form at other Roche facilities throughout the world”.